NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Progress in Phase IIA Ebola Treatment Trial of NV-387 Oral Gummies
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, designed to enroll up to 20 patients with varying disease severity, is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity. Following completion of the trial and evaluation of the results, NanoViricides plans to…







